Our Company
About
Management
Board of Directors
Scientific and Clinical Advisors
Collaborations
Our Technology
CD6 in Immuno-inflammation
EQ001
Publications
Pipeline
Overview
Therapeutic Applications
Graft-Versus-Host Disease
Uncontrolled Asthma
Lupus Nephritis
Clinical Trials
Our commitment to patients
The EQUATE study
The EQUIP study
Expanded Access Policy
Investors
Investor Overview
Stock Information
Stock Quote & Chart
News
Events & Presentations
Financials & Filings
SEC Filings
Corporate Governance
Governance Highlights
Management
Board Of Directors
Committee Composition
Investor FAQ
Contacts
Contacts
Email Alerts
Document Requests
Careers
Contact Us
Menu
HARNESSING NOVEL IMMUNOBIOLOGY
Scroll to top
